- Home
- BKU vs KNSA Comparison
BKU vs KNSA Comparison
Compare BKU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKU | KNSA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BKU | KNSA |
|---|---|---|
| Price | $46.09 | $52.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $51.58 | ★ $58.43 |
| AVG Volume (30 Days) | ★ 914.5K | 742.4K |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | 14.61 | ★ 225.00 |
| EPS | ★ 3.53 | 0.27 |
| Revenue | $21,732,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $16.26 | $37.48 |
| Revenue Next Year | $4.78 | $17.87 |
| P/E Ratio | ★ $13.37 | $71.19 |
| Revenue Growth | 7.45 | ★ 60.09 |
| 52 Week Low | $32.34 | $25.71 |
| 52 Week High | $52.11 | $54.23 |
Technical Indicators
Market Signals| Indicator | BKU | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 66.79 |
| Support Level | $44.10 | $40.67 |
| Resistance Level | $46.29 | N/A |
| Average True Range (ATR) | 1.24 | 2.20 |
| MACD | -0.07 | 0.68 |
| Stochastic Oscillator | 41.45 | 85.60 |
Price Performance
Historical ComparisonAbout BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses. The company also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products including commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.